PR Newswire Clinical TrialsOriginal article
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Data ReadoutpositiveRYBREVANT FASPROLAZCLUZEPositive
AI Analysis
Summary
Johnson & Johnson presented new safety data at WCLC 2026 showing low rates of treatment-related adverse events with RYBREVANT FASPRO plus LAZCLUZE combination therapy when used with prophylactic strategies, with fewer than 1% of patients discontinuing due to treatment-related events at one year.
Clinical Trial Data
Outcome Details
Low rates of rash, blood clots and administration-related reactions observed with subcutaneous treatment and prophylaxis. Fewer than 1% of patients discontinued treatment due to treatment-related events at one year.
Importance:6/10
Sentiment:
0.75
safety datacombination therapyWCLC 2026conference presentationprophylactic strategiessubcutaneous administration
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 15, 2026 3:00 AM